Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3IL
|
|||
| Former ID |
DNCL002022
|
|||
| Drug Name |
ASM8
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Allergic asthma [ICD-11: CA23.0; ICD-10: J45.0] | Phase 2 | [1] | |
| Company |
Pharmaxis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CCR3 messenger RNA (CCR3 mRNA) | Target Info | . | [2] |
| NetPath Pathway | IL3 Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01380236) A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma. U.S. National Institutesof Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.